ICLE 2022 | Current research on anti-CD38 CAR T-cell therapies
Tuna Mutis
• 1 Apr 2022
Tuna Mutis, MD, PhD, Amsterdam University Medical Center, Amsterdam, The Netherlands, gives an overview of his research on developing chimeric antigen receptor (CAR) T-cell therapies targeting CD38. As a result of the development of daratumumab, an anti-CD38 monoclonal antibody for patients with multiple myeloma, efforts to develop efficacious anti-CD3 CAR T-cell therapies are currently underway. Prof. Mutis additionally highlights B-cell maturation antigen (BCMA) as a novel target and dual targeting as a potential strategy to enhance cell therapies. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
